Kalorama: Companion Diagnostic Testing Market Reaches $1.6 Billion
NEW YORK, June 15, 2016 /PRNewswire/ -- According to Kalorama Information, companion diagnostic testing continues to grow as new partnerships are formed and new tests marketed. The healthcare market research firm the values the market at approximately $1.6 billion in 2015, up 33% from two years earlier. In its report the firm uses a broad definition of companion diagnostics market, including both FDA-defined companion diagnostics and other personalized medicine testing. The firm suggests this segment is large and rapidly growing market, as researchers, pharmaceutical companies, and diagnostic companies are now starting to develop personalized medicine tests. The World Market for Companion Diagnostics analyzes the market for these aids in diagnosis that classify patients with disease-specific therapeutic targets that may dramatically improve outcomes.
"Our market estimate in this field is most accurate as it takes into account all paring of tests for any therapeutic purpose," said Bruce Carlson, Publisher of Kalorama Information. "We are looking at strict test/pair combination, but also non-required pharmacogenomics and tests supported by scientific literature but not yet in regulatory model."
As part of its market estimate, Kalorama Information includes:
- Strict FDA defined companion diagnostics.
- Pharmacogenomic biomarkers for which pharmacogenomics information is included in the drug labeling for approved drugs, but not required testing before the drug can be prescribed.
- Biomarkers and Panels – Targeted Genes Supported by Scientific Literature: This includes tests for individual genes supported by the scientific literature and accepted for use in personalized medicine applications, and also panels of these genes.
- Genetic Signatures to Predict Prognosis and/or Best Therapeutic Option
- Antibiotic Resistance or Susceptibility Tests
- Drug Metabolism Tests
- Therapeutic Drug Monitoring – Especially tests that monitor serum blood levels and anti-drug antibodies for biological agents such as infliximab
Kalorama's report lists scores of products on the market and in development and companies involved in deals. It also notes a large amount of partnerships in the area. Companies working in the field of personalized medicine need to understand both the pharmaceutical and diagnostic markets (including regulatory and other issues), but many companies do not have expertise in both fields. This has lead to many agreements and acquisitions, and a large number of diverse deals. The growth in companion diagnostic testing is likely to continue, as many new therapies are being developed and commercialized.
The World Market for Companion Diagnostics covers the world market for companion diagnostic and personalized medicine diagnostics. Market analysis in the report includes the following: world IVD companion diagnostics test market (in vitro diagnostic kits) by region (North America, EU, rest of world), 2015-2020; world IVD companion diagnostics test market by disease segment, 2015 (cancer, other); and worldwide companion diagnostics test services market, 2015 and 2020.
The report provides profiles of selected pharmaceutical companies that are active in the fields of companion diagnostics or personalized medicine. They include companies that market drugs that have associated companion diagnostic tests, pharmaceutical companies that are collaborating with diagnostic companies to develop companion diagnostic tests, and companies with their own internal capabilities and activities in companion diagnostics. These include Pfizer, Inc., Novartis AG, Roche (F. Hoffmann-La Roche Ltd.), Merck & Co., Inc., GlaxoSmithKline plc, and many more.
Also included in the report are profiles of companies that are active in the discovery and/or commercialization of companion diagnostics or other in vitro diagnostic tests for personalized medicine. This includes diagnostic companies that market kits that are used by clinical laboratories, and also diagnostic companies that are commercializing their novel diagnostic tests as a service offered to physicians, with the tests performed in the company's own CLIA certified laboratory. These include Abbott Laboratories, Beckman Coulter, Inc. (a subsidiary of Danaher Corporation), Becton, Dickinson and Company (BD), bioMérieux SA, QIAGEN N.V., and others. The information presented in this report is derived from publicly available information sources such as company reports and announcements, government reports and databases, medical organization reports, medical associations, and other publications. The analysis is based on the author's industry knowledge combined with literature searches and discussions with industry professionals and experts in the areas of point-of-care tests, decentralized healthcare and healthcare economics.
The World Market for Companion Diagnostics can be found at Kalorama Information: http://www.kaloramainformation.com/Companion-Diagnostics-10101302/.
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. Reports can be purchased through Kalorama's website and are also available on www.marketresearch.com and www.profound.com.
We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
Logo - http://photos.prnewswire.com/prnh/20150831/262422LOGO
SOURCE Kalorama Information
Share this article